Main menu

Oxford Nanopore sequencing solutions for cell and gene therapies

  • Published on: November 14 2025
Brochure: biopharma CGT — 2 pages

Overview

Cell and gene therapy development is inherently complex. That is why comprehensive sequencing is essential: it serves as a critical checkpoint at every stage in cell and gene therapy development. However, legacy next-generation sequencing (NGS) methods require fragmentation and amplification steps, erasing critical sample information. Discover how Oxford Nanopore sequencing overcomes these limitations with direct, PCR-free workflows to reveal the true biology of your samples.

In this brochure, find out how nanopore sequencing can be applied in the development of cell, gene, and RNA therapies to provide the data you need to develop better and safer drugs, whilst reducing risk .

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag